share_log

西南证券4月26日发布研报称，给予卫宁健康（300253.SZ）买入评级，目标价格为9.20元。评级理由主要包括：1）医卫信息化收入稳健增长，人效提升利润恢复亮眼；2）“1+X”战略升级推进，WiNEX标杆持续落地；3）前瞻布局AI+医疗信息化，下游景气复苏值得期待。（每日经济新闻）

Southwest Securities released a research report on April 26 stating that it gave Weining Health (300253.SZ) a purchase rating, and the target price was 9.20 yuan. The main reasons for the rating include: 1) steady growth in healthcare informatization reve

Zhitong Finance ·  Apr 26 15:55
Southwest Securities released a research report on April 26 stating that it gave Weining Health (300253.SZ) a purchase rating, and the target price was 9.20 yuan. The main reasons for the rating include: 1) steady growth in healthcare informatization revenue; 2) promotion of “1+X” strategy upgrade and continued implementation of the WineX benchmark; 3) forward-looking AI+ medical informatization, and the recovery of the downstream economy is worth looking forward to. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment